SANTA BARBARA, Calif., June 4 /PRNewswire-FirstCall/ -- Abviva, Inc. (Pink Sheets: ABVV), a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, today provided further details about worldwide patent protection for its breast cancer risk assessment technology.
Abviva appoints W.T. Uniack & Co. as its independent auditor. Abviva is working hard to regain compliance and this is the next step. Uniack will perform the audit for the fiscal years 2008 and 2009. Abviva is moving as quickly as possible to complete these audits.
"We look forward to building shareholder value by completing these audits and becoming fully OTCBB compliant. This is the first of many announcements that will demonstrate the Company's dedication to increasing the Company's bottom line as well as shareholder value," said Barrett Evans, CEO of Abviva, Inc.
Abviva, Inc. is a biomedical company engaged in the innovation, development and commercialization of breast cancer related applications of Mammastatin, a growth inhibitory protein discovered at the University of Michigan Cancer Center that demonstrated anti-breast cancer properties. The discovery was developed into a simple breast cancer diagnostic blood test that demonstrated healthy women have high or normal levels of the protein and women with breast cancer have no detectable or very low levels of the protein. Abviva intends to commercialize the Mammastatin Serum Assay as a reference test through its wholly owned subsidiary laboratory under CLIA certification.
Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
|SOURCE Abviva, Inc.|
Copyright©2010 PR Newswire.
All rights reserved